Abstract: In our study we developed a computational algorithm for nding optimal dosages of antiretroviral drug administration for the stabilization of HIV load at low levels. The novelty is that the pharmacokinetics and pharmacodynamics of the antiretroviral drugs were taken into account. A standard closed-loop control of HIV dynamics was constructed that stabilizes the viral load and the optimal drug administration mode was formulated. We analyze the appropriateness of the 'drug e cacy' based control and its relationship to a realistic drug dosage and kinetic models in the human body. The translation of the e cacy function into drug concentration is implemented via the pharmacodynamics model of the drug e ect. Optimal approximation of the idealized concentration functions is based on the orthogonal projection on linear subspace of drug pharmacokinetics functions.
Human immunode ciency virus (HIV) infections remain a major concern for public health with about 35 million infected individuals worldwide [10] . HIV is a retrovirus that a ects the immune system, and uses its functionality for self-replication. Continuous ongoing virus replication within an infected host leads to a gradual destruction of the immune system and results in AIDS and eventual death. Antiretroviral therapy (ART) based on the use of a combination of three and more pharmaceutical compounds out of the 26 approved drugs provides a basis for long-term control of virus replication [3, 19] . The drugs target di erent steps of the viral life cycle and allow to keep viral loads at low level. This transforms HIV-infected individuals into chronic carriers with prolonged life expectancy. However, ART is rather expensive and associated with side e ects such as hepatotoxicity, neurological disorders and cardiovascular diseases. Therefore, the optimal timing of medication presents an important issue with respect to improving therapy bene ts.
Mathematical modelling and control theory represent promising tools for developing parsimonious and personalized approaches to treatment of HIV-infected individuals. An overview of the progress achieved so far in model-driven analysis and optimal control of HIV infection can be found in [1, 5, 6, 8, 13] . As the virus cannot be eliminated via antiretroviral therapy, the realistic objective in formulating the optimal control problem is the reduction of the viral load. Indeed, the duration of an asymptomatic HIV infection is inversely related to the set-point viral load as shown in [7] . The appropriate framework for designing the corresponding control strategy is based upon the feedback and deviation control [4, 14] . The antiretroviral drugs are given to patients according to the manufacturer's recommendation. It should be noted that research on optimal timing of ART presents a challenge. Drug dynamics in the body is governed by drug-speci c pharmacokinetic models with respective parameters [11, 18, 20] . However, the existing approaches towards the mathematical modelling of optimal therapy design are based upon the so called 'drug e cacy' functions or control variables that can take any values from the speci ed range [1, 6, 8, 14] and thus ignore drug kinetic constraints. We note that in [8] an optimal control problem for three drugs treatment was considered with the drug concentrations in between the dosages administration approximated as average values rather than dynamic quantities.
The purpose of our study was to develop a numerical method for nding an optimal dosage of medication for HIV control taking into account the pharmacokinetics and pharmacodynamics of the antiretroviral drugs. We constructed a closed-loop control of HIV dynamics that stabilizes the viral load and evaluated the optimal drug administration regime. We analyzed the appropriateness of the 'drug e cacy' based control and its relationship to the drug dosage and kinetics in the body. Our study is built upon the previous work on closed-loop control [14] . In Section 2 we present the basic model of HIV dynamics and the feedback-based stabilization procedure. Section 3 considers the pharmacokinetic and pharmacodynamic issues for drug modelling and the algorithm for optimal drug dosage calculation. The numerical implementation and the results are covered in Section 4. Finally, in Section 5 the conclusions are presented.
Basic approach to computational modelling of HIV infection stabilization
We use the following notation in the paper:
-T * (t) density of infected CD4 + T-cells at time t;
-V(t) concentration of free virions (HIV RNA particles) at time t; -e(t) drug e cacy (bounded value representing relative e ect of HIV treatment) at time t; -emax maximal drug e cacy; -C(t) drug concentration at time t; -C drug dosage (amount of administered drug divided by the peripheral blood volume in which it is distributed); -RTI reverse transcriptase inhibitors (antiviral drug inhibiting the transcription of the viral single stranded RNA genome into a double-stranded viral DNA); -PI protease inhibitors (antiviral drug blocking the production of infectious viral particles).
The overall HIV treatment process can be described as follows: the patient takes medication regularly to sustain the drug concentration C(t) around some target value (C(t) C ). The drug concentration determines the drug e cacy e(t) ∈ [ , emax), that eventually determines the reduction of the virus population growth V(t). A conventional approach to modelling HIV treatment is based on predicting the viral population dynamics V(t) given the drug concentration C(t) and the e cacy e(t) function (see, e.g. [20] ). The application of the optimal control methods to HIV infection dynamics consists in computing the optimal e cacy function e(t) in order to minimize some infection severity criterion depending on viral load V(t), immune status and drug quantity (see, e.g. [1, 8] ).
. Basic model of HIV infection dynamics
Today, there exists a broad spectrum of mathematical models addressing various aspects of the HIV infection dynamics and formulated with ordinary, delay-and integro-di erential equations (see the references in [5] ). Most of the research on optimal control of HIV infection dynamics has been performed with rather simple mathematical models considering the target cell infection and the immune response (see Tables 1-2 in [6] ). The widely accepted model used in the studies of the HIV infection is the one presented in [13] . It will be used for illustrative purpose in the present study. We note, that more complex models have been developed that consider di erent types of immune system cells and their characteristic features, infection latency, and virus mutation (see [1, 8, 12] 
( .
Stabilization of HIV dynamics
The implemented algorithm of computing the closed-loop control is based on the work [14] . First, we rewrite system (1.1) using the following vector variables, x, u:
Vector x(t) states HIV dynamics variables and vector u(t) represents control variables for e cacy functions which are normalized to the half-open interval [ , ) . The aim of HIV infected patient ART based optimal control is not a complete elimination of the virus, but the maintenance of its concentration (viral load) at a constant low level. Therefore, the system is to be stabilized in the vicinity of a low viral load equilibrium point X ss , which can be found by setting derivative to zero (ẋ(t) = ). The steady state system of equations reads:
There are three equations with ve unknown variables, which means that two of them can be taken as independent variables while the other three are expressed through them. , which is practically unrealistic. From the above formulas we obtain:
. .
The asymptotic stability of the equilibrium point (x ss , u ss ) can be examined via the analysis of the eigenvalues of Jacobian matrix generating the following characteristic polynomial:
It can be veri ed that the above steady state is stable. The control problem of stabilizing the system at the steady state can be formulated in terms of the deviations ∆x(t) from constant equilibrium values x ss . The control variables also can be splitted into the constant component u ss and time-variant component ∆u(t):
The state and control variables are related via the linearized system of equations:
We consider the quadratic performance criterion to obtain ∆u(t):
where W > and W > are some positively-de ned weighting matrices. It is known that the optimal control law that minimizes the above performance criterion along the trajectories of linearized equation can be calculated from matrix Riccati equation [2] :
(1.2)
Pharmacokinetics and pharmacodynamics based stabilization of the infection
To compute the optimal drug dosages which allow to achieve the drug e cacy required by the stabilizing control function u(t) = uss + ∆u(t), we consider the standard models of pharmacokinetics and pharmacodynamics [11] . Combined pharmacokinetic-dynamic studies seek to characterize the time course of drug e ects.
. Pharmacodynamics
Pharmacodynamics studies the mechanism of interaction between drug and cellular receptors as well as the drug transformation in the cells. Pharmacodynamic models exclusively relate the drug concentration with the pharmacological e ect e(t) = e(t, C(t)). Pharmacodynamics is linked to pharmacokinetics, which encompasses the study of movement of drugs into, through, and out of the body. For any given e cacy function e(t) one can compute the corresponding drug concentration C(t). The basic pharmacodynamic models are presented in Table 1 . The selection of an appropriate pharmacodynamic model depends on drug characteristics as well as the way of its administration. The pharmacodynamic model parameters can be estimated from experimental and clinical data as presented in [20] . The parameter values used in our paper represent some reference values taken from [11] for illustrative purpose. The inversion of the drug e cacy function into the drug concentration pro le is given by the parameterization speci ed in the last column of the above Table. We note that whereas for the sigmoid and time-variant models the concentration function exists for any e cacy function e(t), for the irreversible and indirect link models the di erentiability of e(t) is required.
. Pharmacokinetics
The subject of pharmacokinetics is the study of the spatial-temporal behaviour of the drug concentration in the organism [17] . Pharmacokinetic models suggest explicit functions of drug concentration C(t) = C(t, C , τ), where τ is a time interval between drug administration (e.g., τ = { , , , , , , ...} hours) and C = Table 2 . Basic pharmacokinetic models: the drug concentration functions C(t).
Model
Description
One-compartment with absorption ( CA) drug absorption from gastric system is considered
Two-compartment ( C) second compartment is a drug reservoir e.g. blood and cellular plasma
Two-compartment with absorption ( CA) unites all the previous
M /V is an initial dosage. The classical pharmacokinetic models [11, 17] are based on the concept of compartment: compartmental system is made up of a nite number of constant volume compartments, each of which is homogeneous and well mixed; compartments interact by exchanging material. The basic drug kinetic functions for di erent compartmental models are presented in Table 2 . The identi cation of an appropriate model for a speci c drug requires the drug concentration pro les and is beyond the scope of our study. The parameter values speci ed in Table 2 are for illustrative purpose taken from [17]).
.
Pharmacokinetic-dynamic model based approximation of control function
In this section we seek to nd the best approximation of the feedback control law using the drug concentration functions representing the drug pharmacokinetics in vivo. The continuous drug concentration function to be approximated C(t), t ∈ [ , Tcure] is an element of Hilbert space H = L ( , Tcure). The control (or drug e cacy) function u(t) ≡ e(t) calculated from (1.2) and (1.1) is continuous [2] , therefore the superposition of u(t) and C(u) (see Table 1 ) is also continuous: C ∈ L ( , Tcure). If the control function u(t) is represented at the mesh points dividing the interval [ , Tcure] into M equal subintervals, then the vector C ∈ R M and H in this case is the M-dimensional Euclidean space. We use the following notation for the inner product (·, ·) = (·, ·) H and the norm · = · H . It is practically impossible to achieve an exact match between the theoretical (continuous optimal control function) and the actual drug concentration in blood, since the drug kinetics is governed by an appropriate pharmacokinetic model. If the drug is administered at dose C at time t = , its concentration changes as Tcure] according to one of the models: 
Therefore, all admissible drug concentration functions C Γ (t) are the elements of a linear span of the basis functions
i= . Let us denote the nite linear subspace of H, L Γ = span(Γ i ), i = , . . . , N − . The optimal approximation problem in Hilbert space for given concentration function C is equivalent to the minimization problem for the following functional:
The following statement holds.
Theorem 2.1. The solution of the orthogonal projection problem (2.2) exists, is unique and given by C
* = G − C ,
whereC is the drug pro le function required for optimal feedback stabilization and G is the Gram matrix of the basis functions {Γ
Proof. The Hilbert projection theorem [15] states that for any element of the Hilbert space and any its nite closed subspace there exists a unique best approximation element of that subspace. Therefore, ∀C ∈ H there exists a unique orthogonal projection C * Γ ∈ L Γ such that:
To nd C * Γ , the orthogonal projection procedure (C − C * Γ , Γ i ) = , i = , . . . , N − , generates the following system of linear algebraic equationsC i = (C, Γ i ), depending on the Gramian matrix with elements G ij = (Γ j , Γ i ) for the basis functions L Γ :
The best-t estimate of the dosages vector C * is given by the solution of the linear system GC * =C.
Another way to prove the theorem is to nd the minimum to the functional Z(C ). At the extremum point the following holds: (∇Z)
As the Hessian matrix is constant for all C ∈ R N , and is positive de nite, it follows that Z is a convex functional. Therefore, it has a unique minimum point de ned by ∇Z = .
Overall, both considerations lead to the same system with a positive de nite matrix for the unknown drug dosages GC =C that has a unique solution C * = G − C .
Remark 2.1. The Gram matrix G is a symmetric and Toeplitz one: 
Numerical study . Implementation of the algorithm
The following iterative process to compute the optimal drug dosages allowing to approximate the drug concentration pro le required by the the feedback control law is implemented using MATLAB programming tools. Initially, the control time interval is set [ , Tcure]. Then, a uniform mesh tn, n = , . . . , N, is introduced with the step-size h, such that t N = hN = Tcure. On the set of subintervals [t n− , tn], the control function u(t) and the trajectory x(t) are computed using the following procedure:
(1) compute ∆u(t n− ) = −F n− ∆x(t n− ), where the optimal gain matrix F n− is computed by solving matrix Riccati equation (1.2);
(2) evaluate u(t n− ) = uss + ∆u(t n− ), with u(t n− ) normalized to ≤ u(t n− ) < ; (3) solve the initial value problemẋ(t) = f (x(t), u(t)) on [tn , t n− ] starting at x(t n− ) with u(t) = u(t n− ) to get u(tn).
As the result we generate the (discrete) functions x(tn) converging to x ss and optimal drug e cacy functions u(tn) → uss, respectively. The next stage is to compute the corresponding concentration pro le C(t) for the generated drug e cacy function u(tn) using the speci c pharmacodynamic formula C(u(t)) as indicated in Table 1 . Finally, we solve the linear system GC * =C for C * considering di erent values of time intervals between the drug administration, characterized by the parameter τ = { , , , , , , } hours. Overall, this allows one to estimate the best-t drug dosages vector C * for di erent G(τ) andC(τ).
. Results
We consider the stabilization problem for the HIV infection with the initial conditions that di er from the target steady state values: [T,
. We set the duration of the therapy time Tcure = days and nd the solution of the optimal feedback control problem on a uniform grid with a step (h) of one hour (tn = n/( Tcure)). The controlled dynamics of the viral load V (t, u(t)), uninfected T(t, u(t) ) and infected T-cells populations T * (t, u(t) ) is shown in Fig. 1 .
The closed-loop system is driven to the neighbourhood of the steady state xss. The corresponding control (e cacy) functions u , u are presented in Fig. 2 .
Notably, for this scenario, RTI-type drug is not required in the treatment aimed at the HIV infection stabilization of up to 120-th day, while the PI-type drug should be administered in large quantities: for the rst ten days the patient is supposed to receive the drug amount that brings the e cacy function to almost 1. Then it should be reduced by 50%. After 120 days the required drug e cacy level goes down to 0.14, whereas the e ect of the rst drug should ensure the e cacy function value of about 0.43.
To examine the di erence between the dynamic and static modes of control, we present the solution to the HIV model under the assumption that the control functions take constant values equal to the mean values of drug e cacy function x (t, AUC(u(t) )) (the mean value AUC is the area under function curve divided by therapy time, which are in our case AUC(u ) = .
and AUC(u ) = .
). Figure 3 shows the optimally controlled and time constant control HIV infection dynamics. The di erences in the time course of the state variables between the optimal control-and constant drug e cacy based therapy are quite substantial.
Using the computed e cacy functions, we proceed with the inversion of the required control laws into the drug medication levels using four pharmacodynamic models speci ed in Table 1 . Figure 4 shows the kinetics of the drugs concentrations for the di erent models. The drug concentration functions are rather close to the e cacy function patterns (Fig. 2) although some smoothing of the sharp peak of the PI control law takes place. The resulting functions for indirect link-and irreversible models appear to be quite similar to the emax model. The time-variant model demonstrates the presence of a small linear growth phase in RII drug after 120 
(t, u(t)) and constant controls (CC)T(t, AUC(u)), (b) infected CD4 + T-cells and (c) viral load dynamics under optimal e cacy T * (t, u(t)), V(t, u(t)) and constant e cacy functionsT * (t, AUC(u)),Ṽ(t, AUC(u)) regimes.
days rather than a stabilization at a steady sate level. The observed behaviours suggest that further analysis of the optimal drug dosage administration performed only for the emax model will be su ciently instructive.
To nd the optimal doses of the ART drugs required to achieve the target concentrations speci ed by C(t) we proceed with the orthogonal projection algorithm outlined in the previous section. To this end linear systems of equations with the Gram matrix for the set of basis functions Γ i (t) for every pharmacokinetic model speci ed in Table 2 are generated. By solving the system of equations we get the required values of C * vector and the approximating drug kinetic pro le C Γ (t). Figure 5 gives an example of C Γ (t) behaviour during the rst ve days after initiation of the PI-type drug therapy. The behaviour of C Γ (t) for RTI of drug treatments is shown in Fig. 6 . Here we consider one-compartment model with absorption and the time intervals between the drug intake ranging from 4 to 12 hours: τ = { , , }.
Figures 5 and 6 also show the drug doses C * administered sequentially at times t i = iτ required to closely achieve the target concentration function C(t). One can observe that the values of C * are decreasing with smaller τ values. Indeed with shorter intervals between drug administrations larger quantities of the drug remain in the body and consequently the required drug amount to reach the target level becomes smaller. Obviously, the resulting drug concentration functions depend on the τ value and di er from one another. One can examine the problem of nding an optimal dosage interval τ. The optimality can be addressed by considering an approximation criterion expressed as a relative error of the di erence between the target drug concentration and the achievable concentration function in the Euclidean norm:
The relative approximation errors were computed for all pharmacokinetics models and values of τ ranging from 2 to 24 hours. The results are presented in Table 3 for RTI drug and Table 4 for PI drug. One can see that the optimal interval between drug administration is the one with a minimal error. The tables show that the best approximations for both drugs are obtained for the smallest τ values equal to two hours between intakes. The models with absorption provide a better approximation. Figure 7 depicts the drug concentration Figure 7 . The long-term dynamics of the concentration of the RTI-(a) and PI-type (b) of the antiretroviral drugs suggested by the solution of the optimal control problem C(t) and the best approximation to it attainable for the 'one-compartment with absorption' pharmacokinetics model C Γ (t) with a short-interval between the administration of the drug τ = hours.
functions for a long-term treatment for one-compartment model with absorption (Tcure = (days)). One can see that the approximating concentration functions oscillate in the close vicinity of the target theoretical functions in relation to the basic drug kinetics model Γ(t). The oscillations increase with increasing dosages C or with time intervals τ between the drug intakes.
To verify the computed approximation C Γ (t) for the drug concentration function C(t) we solved numerically the minimization problem (2.2) for the functional Z(C ) using MATLAB function 'fminunc' with zero initial guess vector. By nding the minimum valuesĈ = arg min(Z(C )) we evaluated Cver = N i= Ĉ* Γ i to be compared with the optimal projection based solution. The relative di erence between the two functions C Γ − Cver / C Γ appears to be less than .
for all models and τ values used in the analysis and by two orders smaller than the relative approximation error.
Discussion
In the present study we examined the link between idealized control laws for the HIV infection obtained via the application of the optimal control theory to mathematical models of HIV infection dynamics. This goes beyond existing approaches towards computational modelling of HIV control which are based upon the assumption that the e cacy or control function can take any value at all times. A computational algorithm was developed that enables to determine the drug dosages C that are required to achieve an optimal drug concentration C(t) to have the e cacy e(t) that stabilizes the viral load below a certain level V(t) ≤V and uninfected CD4 + T-cells above a certain level T(t) ≥T. The algorithm approximates the e ect of theoretical control functions by an optimal drug administration regime with the dose of the drug being an optimized parameter. The dependence on time intervals between the drug administration was explored. The developed algorithm has a modular structure so that the speci c HIV infection dynamic model or the pharmacokinetics/-dynamics model of the drugs can be replaced by re ned ones. Our results indicate that in order to ensure a good approximation of the drug concentration kinetics suggested by the optimal control of the infection dynamics the intervals between the drug administration should be smaller and a two-fold reduction leads to a proportionate decrease in the relative error of the approximation. The pharmacokinetics models with absorption provide a better approximation to the target concentration pro le than those without absorption. Previous mathematical modelling studies on HIV dynamics and control considered the e ect of drug treatment through an idealized 'e cacy' or control function term. In medical practice, the drug administration is constrained by the approved protocols and is based on prescription of standard doses of ART drugs in a regular manner [16] . In addition, the drug action is constrained by the pharmacokinetics and pharmacodynamics of the drug. Special clinical studies need to be conducted in order to identify the functions describing the drug e cacy and the kinetics of the drug in the body.
The design of patient-individual dosing regimes for HIV infection treatment remains a challenge. Further progress in this direction requires the parameterization of the side e ects and the cost of the drugs, and considerations of multiscale regulation of virus infection and immune response dynamics. The rst study along these lines was presented recently in [8] . Another important direction of analysis will be to explore the optimal drug administration regimen by varying both the dose and the timing between the interventions. Finally, our approach will be extended to consider the practically used therapies based on the combination of three and more antiviral drugs and to include immunomodulatory treatments.
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